They are widely exploited by loop and thiazide diuretics to treat hypertension78. SLC12A3 is currently a target for eight approved and marketed molecular agents, while SLC12A1 is targeted by ten76. SLC12 have also been discussed as possible targets for the treatment of neurological disorders such as seizures and neuropathic pain79.
The gastric H+/K+-ATPase, which makes up 12% of all transporter targets, is the molecular target for the class of antisecretory drugs knows as proton-pump inhibitors (PPIs). Examples of PPIs include esomeprazole, lansoprazole, omeprazole, and pantoprazole. The effectiveness of these drugs is due to the fact that H+/K+-ATPase is the enzyme responsible for gastric acid secretion and their mechanism of action involves covalent binding of the activated drug to the enzyme80. Na+/K+-ATPase is the target for the cardiac glycoside